Quote:You have absolutely no idea what you are talking about.


A quick google search yields the following:


In the United States, as of 2015, with the acquisition of U.S. marketing of Daraprim tablets by Turing Pharmaceuticals, pyrimethamine has become a single-source and specialty pharmacy item, and the cost of pyrimethamine has increased. The cost of a monthly course for a person on 75 mg rose to about $75,000/month, from $13/tablet to $833/tablet, or $750 per tablet per a New York Times report from September 2015. Outpatients can no longer obtain pyrimethamine from their community pharmacy, but only through a single dispensing pharmacy, Walgreens Specialty Pharmacy, and institutions can no longer order from their general wholesaler, but have to set up an account with the Daraprim Direct program.


In India, multiple combinations of this tablet are available for a price ranging from U.S. $0.05–$0.10 each (3–7 rupees).


...


Where does it say the cost increase is to find alternatives? How does that even make sense to you?


Furthermore:


It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.


...


It's essential for people with HIV. It's also anti malarial. Bottom line, your characteristic of it is competely wrong.


This is an example of greed. Plain and simple.

Quote: 

Daraprim, known generically as pyrimethamine, is used mainly to treat toxoplasmosis, a parasite infection that can cause serious or even life-threatening problems for babies born to women who become infected during pregnancy, and also for people with compromised immune systems, like AIDS patients and certain cancer patients.

 
Martin Shkreli, the founder and chief executive of Turing, said that the drug is so rarely used that the impact on the health system would be minuscule and that Turing would use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.
 
“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” Mr. Shkreli said. He said that many patients use the drug for far less than a year and that the price was now more in line with those of other drugs for rare diseases.